The phase 3 LITESPARK-005 trial compared single-agent belzutifan to everolimus in patients with advanced ccRCC whose disease progressed following both an ICI and a VEGF-TKI.18 The results demonstrated a PFS benefit in patients who received belzutifan compared to everolimus (21 vs 17.2 months, HR 0.75, 95% CI, 0.63-0.90) without new or unexpected safety signals for belzutifan. Here, VEGFA is linked to nonpapillary renal cell carcinoma.